AstraZeneca today had another big round of dismal revenue numbers to explain today. With generic rivals tearing at some of its key franchises, the pharma giant reported a 13% drop in revenue for the first quarter.
AstraZeneca's partnership spree of the last two months has gone Down Under. As the company shrinks its internal research work force, AstraZeneca has tapped Brisbane, Australia-based Alchemia to hunt for small molecule drugs against multiple disease targets.
While the success rate in developing new disease treatments remains alarmingly low, a cadre of R&D executives from some of the world's biggest drug developers insisted at BIO that they've zeroed in on a number of ways to boost the chance a promising drug will actually reach patients.
AstraZeneca and Bind Therapeutics have joined forces in the creation of a kinase inhibitor nanotech for treating cancer, part of Bind's Accurin line of delivery platforms.
AstraZeneca forged two oncology development deals on either side of the Atlantic.
At least one big AstraZeneca shareholder isn't concerned about CEO Pascal Soriot's pay package.
While AstraZeneca's busy business development team was fashioning a new discovery deal with Bind Therapeutics in Cambridge, MA, it was also polishing a pact in the other Cambridge.
The drug giant, which is in the process of renovating its R&D wing, has hired on the crafty Cambridge, MA-based biotech Bind Therapeutics to work on a kinase inhibitor nanotech drug for treating cancer.
They're not exactly carrying pitchforks and torches, but some activist shareholders are demanding satisfaction on executive pay.
As antibiotic resistance grows in the U.S. with the rise in increasingly deadly bacteria, nicknamed 'nightmare bacteria,' a new report has identified that only 7 drugs are in development to combat these superbugs.